Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Treatment Options in Neurology

04-05-2024 | Dementia | Review

Updates in Fluid, Tissue, and Imaging Biomarkers for Dementia with Lewy Bodies and Implications for Biologically Based Disease Definitions

Author: Samantha K. Holden, MD, MS

Published in: Current Treatment Options in Neurology

Login to get access

Abstract

Purpose of Review

Dementia with Lewy bodies (DLB) remains underrecognized and underdiagnosed due to its clinical and pathological heterogeneity. Diagnosis currently relies on recognition of clinical features and imaging and neurophysiologic biomarkers. However, clinical features are less obvious in mixed neurodegenerative pathologies, advanced imaging techniques are often inaccessible, and current DLB indicative biomarkers do not directly identify Lewy pathology.

Recent Findings

Seed amplification assay techniques have allowed for in vivo detection of pathological alpha-synuclein protein in the cerebrospinal fluid, blood, and dermal biosamples. Incorporation of co-pathology markers and refinement of the application and interpretation of existing tests for DLB, including brain and cardiac imaging, are also ongoing. Strategic combinations of Lewy biomarkers with other markers of neurodegeneration and neuroinflammation could create individualized patient profiles for diagnosis, prognosis, treatment selection, and response monitoring.

Summary

Continued validation and technical harmonization efforts will be needed prior to widespread clinical application of new Lewy body biomarkers. Combining existing and novel DLB and co-pathology biomarkers, along with thorough clinical evaluation, will lead to increased reliability and accuracy of etiological dementia diagnosis. Use of biomarker profiles and biologically based disease definitions will improve care and accelerate treatment discovery for people living with DLB.
Literature
1.
Kane JPM, Surendranathan A, Bentley A, Barker SAH, Taylor JP, Thomas AJ, et al. Clinical prevalence of Lewy body dementia. Alzheimers Res Ther. 2018;10(1):19.CrossRefPubMedPubMedCentral
2.
Hogan DB, Fiest KM, Roberts JI, Maxwell CJ, Dykeman J, Pringsheim T, et al. The prevalence and incidence of dementia with Lewy bodies: a systematic review. Can J Neurol Sci. 2016;43(Suppl 1):S83-95.CrossRefPubMed
3.
• Gibson LL, Abdelnour C, Chong J, Ballard C, Aarsland D. Clinical trials in dementia with Lewy bodies: the evolving concept of co-pathologies, patient selection and biomarkers. Curr Opin Neurol. 2023;36(4):264–75. Thorough overview of current state of the field in dementia with Lewy body clinical trials and suggestions for future work.
4.
McKeith IG, Boeve BF, Dickson DW, Halliday G, Taylor JP, Weintraub D, et al. Diagnosis and management of dementia with Lewy bodies: fourth consensus report of the DLB Consortium. Neurology. 2017;89(1):88–100.CrossRefPubMedPubMedCentral
5.
Waqar S, Khan H, Zulfiqar SK, Ahmad A. Skin biopsy as a diagnostic tool for synucleinopathies. Cureus. 2023;15(10): e47179.PubMedPubMedCentral
6.
7.
Scott GD, Arnold MR, Beach TG, Gibbons CH, Kanthasamy AG, Lebovitz RM, et al. Fluid and tissue biomarkers of Lewy body dementia: report of an LBDA symposium. Front Neurol. 2021;12: 805135.CrossRefPubMed
8.
Donadio V, Incensi A, Rizzo G, Capellari S, Pantieri R, Stanzani Maserati M, et al. A new potential biomarker for dementia with Lewy bodies: skin nerve α-synuclein deposits. Neurology. 2017;89(4):318–26.CrossRefPubMed
9.
Kim JY, Illigens BM, McCormick MP, Wang N, Gibbons CH. Alpha-synuclein in skin nerve fibers as a biomarker for alpha-synucleinopathies. J Clin Neurol. 2019;15(2):135–42.CrossRefPubMedPubMedCentral
10.
• Yoo D, Bang JI, Ahn C, Nyaga VN, Kim YE, Kang MJ, et al. Diagnostic value of α-synuclein seeding amplification assays in α-synucleinopathies: a systematic review and meta-analysis. Parkinsonism Relat Disord. 2022;104:99–109. Recent review and meta-analysis of seed amplification assay studies for alpha-synucleinopathies.
11.
12.
•• Bellomo G, De Luca CMG, Paoletti FP, Gaetani L, Moda F, Parnetti L. α-Synuclein seed amplification assays for diagnosing synucleinopathies: the way forward. Neurology. 2022;99(5):195–205 Expert consensus and roadmap for continued development, validation, and operationalization of seed amplification assay techniques for synucleinopathies.
13.
• Donadio V, Wang Z, Incensi A, Rizzo G, Fileccia E, Vacchiano V, et al. In vivo diagnosis of synucleinopathies: a comparative study of skin biopsy and RT-QuIC. Neurology. 2021;96(20):e2513–24. Head-to-head comparison of IF-based to SAA-based alpha-synuclein detection techniques for discrimination of synucleinopathies (PD, DLB, MSA, pure autonomic failure) from non-synucleinopathies (AD, progressive supranuclear palsy, corticobasal syndrome, vascular dementia, frontotemporal dementia, drug-induced parkinsonism).
14.
Peña-Bautista C, Kumar R, Baquero M, Johansson J, Cháfer-Pericás C, Abelein A, et al. Misfolded alpha-synuclein detection by RT-QuIC in dementia with Lewy bodies: a systematic review and meta-analysis. Front Mol Biosci. 2023;10:1193458.CrossRefPubMedPubMedCentral
15.
Bellomo G, Toja A, Paolini Paoletti F, Ma Y, Farris CM, Gaetani L, Salvadori N, Chiasserini D, Wojdaƚa AL, Concha-Marambio L, Parnetti L. Investigating alpha-synuclein co-pathology in Alzheimer's disease by means of cerebrospinal fluid alpha-synuclein seed amplification assay. Alzheimers Dement. 2024. Epub ahead of print. PMID: 38323747. https://​doi.​org/​10.​1002/​alz.​13658.
16.
McKeith IG, Ferman TJ, Thomas AJ, Blanc F, Boeve BF, Fujishiro H, et al. Research criteria for the diagnosis of prodromal dementia with Lewy bodies. Neurology. 2020;94(17):743–55.CrossRefPubMedPubMedCentral
17.
Phillips JR, Matar E, Ehgoetz Martens KA, Moustafa AA, Halliday GM, Lewis SJG. Exploring the sensitivity of prodromal dementia with Lewy bodies research criteria. Brain Sci. 2022;12(12):1594.CrossRefPubMedPubMedCentral
18.
Grossauer A, Hemicker G, Krismer F, Peball M, Djamshidian A, Poewe W, et al. α-Synuclein seed amplification assays in the diagnosis of synucleinopathies using cerebrospinal fluid-a systematic review and meta-analysis. Mov Disord Clin Pract. 2023;10(5):737–47.CrossRefPubMedPubMedCentral
19.
Poggiolini I, Gupta V, Lawton M, Lee S, El-Turabi A, Querejeta-Coma A, et al. Diagnostic value of cerebrospinal fluid alpha-synuclein seed quantification in synucleinopathies. Brain. 2022;145(2):584–95.CrossRefPubMed
20.
Chouliaras L, Thomas A, Malpetti M, Donaghy P, Kane J, Mak E, et al. Differential levels of plasma biomarkers of neurodegeneration in Lewy body dementia, Alzheimer’s disease, frontotemporal dementia and progressive supranuclear palsy. J Neurol Neurosurg Psychiatry. 2022;93(6):651–8.CrossRefPubMed
21.
Surendranathan A, Su L, Mak E, Passamonti L, Hong YT, Arnold R, et al. Early microglial activation and peripheral inflammation in dementia with Lewy bodies. Brain. 2018;141(12):3415–27.CrossRefPubMedPubMedCentral
22.
23.
Baiardi S, Quadalti C, Mammana A, Dellavalle S, Zenesini C, Sambati L, et al. Diagnostic value of plasma p-tau181, NfL, and GFAP in a clinical setting cohort of prevalent neurodegenerative dementias. Alzheimers Res Ther. 2022;14(1):153.CrossRefPubMedPubMedCentral
24.
Gonzalez MC, Ashton NJ, Gomes BF, Tovar-Rios DA, Blanc F, Karikari TK, et al. Association of plasma p-tau181 and p-tau231 concentrations with cognitive decline in patients with probable dementia with Lewy bodies. JAMA Neurol. 2022;79(1):32–7.CrossRefPubMed
25.
Del Campo M, Vermunt L, Peeters CFW, Sieben A, Hok AHYS, Lleó A, et al. CSF proteome profiling reveals biomarkers to discriminate dementia with Lewy bodies from Alzheimer´s disease. Nat Commun. 2023;14(1):5635.CrossRefPubMedPubMedCentral
26.
Combi R, Salsone M, Villa C, Ferini-Strambi L. Genetic architecture and molecular, imaging and prodromic markers in dementia with Lewy bodies: state of the art, opportunities and challenges. Int J Mol Sci. 2021;22(8):3960. PMID: 33921279; PMCID: PMC8069386. https://​doi.​org/​10.​3390/​ijms22083960.
27.
Alzghool OM, van Dongen G, van de Giessen E, Schoonmade L, Beaino W. α-Synuclein radiotracer development and in vivo imaging: recent advancements and new perspectives. Mov Disord. 2022;37(5):936–48.CrossRefPubMedPubMedCentral
28.
McKeith I, O’Brien J, Walker Z, Tatsch K, Booij J, Darcourt J, et al. Sensitivity and specificity of dopamine transporter imaging with 123I-FP-CIT SPECT in dementia with Lewy bodies: a phase III, multicentre study. Lancet Neurol. 2007;6(4):305–13.CrossRefPubMed
29.
30.
Jreige M, Kurian GK, Perriraz J, Potheegadoo J, Bernasconi F, Stampacchia S, et al. The diagnostic performance of functional dopaminergic scintigraphic imaging in the diagnosis of dementia with Lewy bodies: an updated systematic review. Eur J Nucl Med Mol Imaging. 2023;50(7):1988–2035.CrossRefPubMedPubMedCentral
31.
Galli A, Pilotto A, Chiarini B, Giunta M, Corbo D, Tirloni C, et al. Occipital atrophy signature in prodromal Lewy bodies disease. Alzheimers Dement (Amst). 2023;15(4): e12462.CrossRefPubMed
32.
Imabayashi E, Soma T, Sone D, Tsukamoto T, Kimura Y, Sato N, et al. Validation of the cingulate island sign with optimized ratios for discriminating dementia with Lewy bodies from Alzheimer’s disease using brain perfusion SPECT. Ann Nucl Med. 2017;31(7):536–43.CrossRefPubMedPubMedCentral
33.
Ge J, Lin H, Chen K, Wang M, He Z, Lu J, et al. Optimized cingulate island sign in discriminating dementia with Lewy bodies from Alzheimer disease. Clin Nucl Med. 2023;48(5):400–3.CrossRefPubMedPubMedCentral
34.
Seredenina T, Vokali E, Dreyfus N, Chevallier E, Afroz T, Jaquier T, et al. Discovery and optimization of the first-in-class TDP-43 PET tracer. Alzheimer’s & Dementia. 2023;19(S13): e075525.CrossRef
35.
Slaets S, Van Acker F, Versijpt J, Hauth L, Goeman J, Martin JJ, et al. Diagnostic value of MIBG cardiac scintigraphy for differential dementia diagnosis. Int J Geriatr Psychiatry. 2015;30(8):864–9.CrossRefPubMed
36.
Matsubara T, Kameyama M, Tanaka N, Sengoku R, Orita M, Furuta K, et al. Autopsy validation of the diagnostic accuracy of (123)I-metaiodobenzylguanidine myocardial scintigraphy for Lewy body disease. Neurology. 2022;98(16):e1648–59.CrossRefPubMedPubMedCentral
37.
Sakamoto F, Shiraishi S, Ogasawara K, Tsuda N, Nakagawa M, Tomiguchi S, et al. A diagnostic strategy for Lewy body disease using DAT-SPECT, MIBG and Combined index. Ann Nucl Med. 2020;34(6):415–23.CrossRefPubMed
38.
• Quadalti C, Palmqvist S, Hall S, Rossi M, Mammana A, Janelidze S, et al. Clinical effects of Lewy body pathology in cognitively impaired individuals. Nat Med. 2023;29(8):1964–70. Implications of utilization of SAA techniques for more accurate and reliable classification of cognitive impairment syndromes in a memory disorders clinic cohort.
39.
• Palmqvist S, Rossi M, Hall S, Quadalti C, Mattsson-Carlgren N, Dellavalle S, et al. Cognitive effects of Lewy body pathology in clinically unimpaired individuals. Nat Med. 2023;29(8):1971–8. Implications of utilization of SAA techniques for accurate and reliable screening and development of risk profiles for synucleinopathies.
40.
Alam JJ, Maruff P, Doctrow SR, Chu HM, Conway J, Gomperts SN, et al. Association of plasma phosphorylated tau with the response to neflamapimod treatment in patients with dementia with Lewy bodies. Neurology. 2023;101(17):e1708–17.CrossRefPubMedPubMedCentral
41.
Pillai JA, Bena J, Tousi B, Rothenberg K, Keene CD, Leverenz JB. Lewy body pathology modifies risk factors for cerebral amyloid angiopathy when comorbid with Alzheimer's disease pathology. Alzheimers Dement. 2024. PMID: 38353367. https://​doi.​org/​10.​1002/​alz.​13704.
42.
•• Simuni T, Chahine LM, Poston K, Brumm M, Buracchio T, Campbell M, et al. A biological definition of neuronal α-synuclein disease: towards an integrated staging system for research. Lancet Neurol. 2024;23(2):178–90. Potential paradigm-shifting reclassifications of Lewy body disorders using biological definitions.
43.
•• Höglinger GU, Adler CH, Berg D, Klein C, Outeiro TF, Poewe W, et al. A biological classification of Parkinson’s disease: the SynNeurGe research diagnostic criteria. Lancet Neurol. 2024;23(2):191–204. Potential paradigm-shifting redefinition of Parkinson’s disease using biological definitions.
44.
Jack CR Jr, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, et al. NIA-AA research framework: toward a biological definition of Alzheimer’s disease. Alzheimers Dement. 2018;14(4):535–62.CrossRefPubMed
45.
Siderowf A, Concha-Marambio L, Lafontant DE, Farris CM, Ma Y, Urenia PA, et al. Assessment of heterogeneity among participants in the Parkinson’s Progression Markers Initiative cohort using α-synuclein seed amplification: a cross-sectional study. Lancet Neurol. 2023;22(5):407–17.CrossRefPubMedPubMedCentral
Metadata
Title
Updates in Fluid, Tissue, and Imaging Biomarkers for Dementia with Lewy Bodies and Implications for Biologically Based Disease Definitions
Author
Samantha K. Holden, MD, MS
Publication date
04-05-2024
Publisher
Springer US
Published in
Current Treatment Options in Neurology
Print ISSN: 1092-8480
Electronic ISSN: 1534-3138
DOI
https://doi.org/10.1007/s11940-024-00791-w
Image Credits